CAM
AARD

Cormorant Asset Management’s Aardvark Therapeutics AARD Stock Holding History

Cormorant Asset Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-800,189
Closed -$10.8M – 44
2025
Q2 		$10.8M Hold
800,189
– – 0.81% 27
2025
Q1 		$6.01M Buy
+800,189
New +$8.98M 0.45% 36

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cormorant Asset Management's AARD Position: Q3 2025 in Review

Cormorant Asset Management sold out of Aardvark Therapeutics (AARD) in Q3 2025, closing a stake of 800,189 shares — an estimated $10.8M sold.

Cormorant Asset Management first reported a position in AARD in Q1 2025 and held it in 2 quarters. The position peaked at $10.8M in Q2 2025. 49 funds tracked by Wall St. Rank hold AARD as of Q3 2025.

  • Cormorant Asset Management reported no remaining Aardvark Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cormorant Asset Management sold 800,189 Aardvark Therapeutics shares in Q3 2025, an estimated $10.8M.
  • Cormorant Asset Management first reported a position in Aardvark Therapeutics in Q1 2025 and held it in 2 quarters.
  • Cormorant Asset Management's Aardvark Therapeutics position peaked at $10.8M in Q2 2025.
  • 49 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q3 2025.

Based on Cormorant Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.